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Objective. A growing body of evidence suggests
that real-time electronic assessments of pain are pref-
erable to traditional paper-and-pencil measures. We
used electronic assessment data derived from a study of
patients with fibromyalgia (FM) to examine variability
of pain over time and to investigate the implications of
pain fluctuation in the context of a clinical trial.
Methods. The study group comprised 125 patients
with FM who were enrolled in a randomized, placebo-
controlled trial of milnacipran. Pain intensity levels
were captured in real time by participants using elec-
tronic diaries. Variability in pain was assessed as the
standard deviation of pain entries over time (pain
variability index [PVI]).
Results. Substantial between-subject differences
in pain variability were observed (mean  SD PVI
1.61  0.656 [range 0.27–4.05]). The fluctuation in pain
report was constant over time within individuals (r 
0.664, P < 0.001). Individuals with greater variability
were more likely to be classified as responders in a drug
trial (odds ratio 6.14, P  0.006); however, this associ-
ation was primarily attributable to a greater change in
pain scores in individuals receiving placebo (r  0.460,
P  0.02) rather than active drug (r  0.09, P > 0.10).
Conclusion. Among individuals with FM, there
were large between-subject differences in real-time pain
reports. Pain variability was relatively constant over
time within individuals. Perhaps the most important
finding is that individuals with larger pain fluctuations
were more likely to respond to placebo. It is not clear
whether these findings are applicable only to patients
with FM or whether they may also be seen in patients
with other chronic pain conditions.
Clinical practice as well as research data indicate
that the intensity of chronic pain typically is not constant
(1–3). This phenomenon may be particularly true in
patients with fibromyalgia (FM) (4,5). FM is defined by
the presence of widespread pain and tenderness (6) and
affects 2–4% of the population (7). Within a single day,
an individual with FM may note that his or her level of
pain varies greatly; it is not uncommon for pain scores
on a 10-cm visual analog scale (VAS) to range from 2 to
10 (5). This variability in pain magnitude reflects a
volatility of pain in some individuals, yet relatively few
studies have examined this characteristic.
Variation in the intensity of chronic pain has
been thought to arise from the following 2 sources:
systematic trends in pain levels that may be attributable
to the pathogenesis of the condition (1–3), or fluctua-
tions about a mean pain level that lack any underlying
trend (1). Although some investigators have suggested
that individuals with less predictable pain (i.e., no trend)
have more depressive symptoms (2), this has not been
confirmed by others (3).
The lack of studies focusing on pain variability
within individuals over time may be due, in part, to the
limits of previous data-recording methods, such as
pencil-and-paper diaries (8). These problems have been
largely overcome by the use of electronic diaries that
capture symptoms in real time, using high sampling
densities (9). We examined the within-subject pain vari-
ability across time in individuals with FM who were
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enrolled in a clinical trial in which electronic diary
methods were used.
The main questions of interest were as follows:
What is the within- and between-subject variability of
FM pain over time? How does pain variability differ
across subjects? Finally, is there any information about
an individual’s pain variability that may be helpful in
designing clinical trials in FM?
PATIENTS AND METHODS
Phase II drug trial of milnacipran in FM. The study
group comprised 125 patients with FM who were enrolled in a
multicenter drug trial of milnacipran (a dual serotonin/
norepinephrine reuptake inhibitor) versus placebo (10).
Briefly, participants were randomized to receive either mil-
nacipran or placebo after a 2-week baseline (observational)
period and were followed up longitudinally for 12 weeks.
Patients with FM who were 18–75 years of age and met
the American College of Rheumatology 1990 criteria for FM
(11) were included in the study. Key exclusion criteria included
severe psychiatric illness (although individuals with major
depression or generalized anxiety disorder were not excluded);
risk of suicide according to the investigator’s judgment; alcohol
or drug abuse; history of significant cardiovascular, respira-
tory, endocrine, genitourinary, liver, or kidney disease; sys-
temic infection; cancer or current chemotherapy; significant
sleep apnea; life expectancy of 1 year; and active peptic ulcer
or inflammatory bowel disease. All participants gave informed
consent, and the protocol was approved by the relevant
institutional review boards.
Outcomes. Each participant carried a Palm-based elec-
tronic diary (invivodata, Pittsburgh, PA) and was prompted at
random intervals (a mean of 3.4 times per day) to enter his or
her pain level, using an anchored logarithmic scale (the
Gracely Box Scale [GBS]; range 0–132) (12). These values
were scaled down by a factor of 6.6 to facilitate comparison
with the original GBS (range 0–20).
Statistical analysis. Calculation of the pain variability
index (PVI). For each participant, the standard deviation of
sequential entries within 2-week time blocks was used as the
primary measure of the variability or spread in the data (PVI).
This outcome was chosen because of its ability to capture both
systematic and nonsystematic fluctuations in pain. In addition,
this approach makes fewer assumptions about the structure of
the data, such as averaging pain levels across or within days.
The PVI was calculated separately for each individual and was
then used to create a histogram representing all study partic-
ipants. Mean pain levels were also calculated as the average of
all entries over 2-week time blocks.
Distribution properties of the PVI. To test for ceiling or
floor effects, the population was divided into quartiles based
on individual PVI scores obtained during the first 2 (baseline)
weeks. Histograms of the mean pain scores for the upper
(highly variable) and lower (less variable) PVI quartiles were
compared for skewness.
Stability of the PVI over time. To examine the stability
of the measure, individual PVI scores during the 2 baseline
weeks and the final 2 weeks of the trial (12 weeks later) were
compared using a bivariate Pearson’s correlation.
Relationship of the PVI to treatment responsiveness. To
determine the relationship between pain variability and re-
sponsiveness to treatment (milnacipran or placebo), 3 analyses
were performed: logistic regression, linear regression, and
univariate correlations. For the logistic regression analysis, the
binary response criterion (4-unit change in GBS from baseline
to the end of treatment, which represents an 50% improve-
ment in pain [13]) measured with the electronic diary was used
as the dependent variable. This criterion was chosen because it
is within the range to designate clinical pain responders (13)
and is used here to designate treatment responders. Treatment
assignment (milnacipran or placebo) and ln(PVI) were entered
as predictors. Age, duration of FM, and race (white  1,
nonwhite  0) were also added as additional covariates.
Goodness of fit was assessed with the Hosmer–Lemeshow test.
For the linear regression analysis, the above covariates, in
addition to the mean level of pain at baseline, were used to
predict change in the mean level of pain (baseline  end).
For the univariate analysis, correlations were made
between ln(PVI) and the change in the mean electronic diary
pain scores (baseline  end) for individuals receiving placebo
or milnacipran. PVI data were transformed to the log of PVI to
better approximate the normal distribution needed to meet the
assumption of the statistical methods being used. Graphs of
random prompt entries of pain versus time were made for all
milnacipran responders, to examine the time course of drug
application on real-time pain assessment. A t-test was per-
formed to detect differences in baseline PVI scores between
individuals in whom either an exponential or a linear trend in
pain was observed.
Analyses were performed using SPSS version 12.0.1
(SPSS, Chicago, IL) and SAS version 8.02 (SAS Institute,
Cary, NC) software.
RESULTS
Demographics. The study population (n  125)
comprised predominantly middle-age (mean  SD age
47.05  11.15 years) women (n  122), which is consis-
tent with the epidemiology of FM (14,15). Most of the
subjects (n  105) were white (12 were Hispanic, 5 were
African American, 1 was Asian, and 2 were of other
ethnicity), and most reported high levels of pain
(mean  SD pain score 6.90  1.78) (on a 10-cm VAS)
at baseline. The mean  SD duration of FM was 4.06 
4.16 years.
Characteristics of the PVI. Within- and between-
subject variation in the PVI. To examine the degree of
variability in pain across all participants, a between-
subject histogram of PVI values was created for data
collected during the 2-week baseline period (Figure 1A).
This distribution had a single mode and was skewed
toward higher values (mean  SD PVI 1.61  0.656; P
 0.002). A logarithmic transformation provided a good
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fit to a normal distribution for PVI (P  0.20). A large
spread in the PVI was observed between subjects (PVI
range 0.27–4.05), indicating significant variation in real-
time measurements of pain across participants.
Figures 1B and C depict the raw pain scores for 2
different participants tracked longitudinally over 14
baseline days. Although these 2 individuals had similar
mean pain scores (11.14 for participant 1 and 11.03 for
participant 2), their pain score variability was noticeably
different (for participant 1, PVI  0.27; for participant 2,
PVI  2.78).
Ceiling or floor effects. To test for ceiling or floor
effects, mean pain score distributions for the upper
(more variable) and lower (less variable) PVI quartiles
were investigated for asymmetries. Similar pain scores
would be predicted if ceiling or floor effects were absent.
The skewness and range in pain scores were relatively
similar between quartiles (skewness [SEM] for the lower
quartile 0.26 [0.42], for the upper quartile 0.30 [0.42];
range for the lower quartile 9.25–17.49, for the upper
quartile 5.33–16.57), suggesting that ceiling and/or floor
effects were not largely responsible for the between-
subject variability in the PVI.
Trait variability. To assess whether symptom vari-
ability may represent a trait, we examined the correla-
tion of the PVI observed at 2 different time periods
(baseline versus 12 weeks later). The PVI within indi-
viduals was highly correlated over time (r  0.664, P 
0.001), suggesting that this is a relatively stable con-
struct.
Effects of PVI in a drug trial. Association of PVI
with response to placebo. We next investigated the extent
that pain variability (PVI) influenced binary responder
classification as assessed by electronic diary methods in
a drug trial. A logistic regression on responder status was
performed using age, race, duration of FM, treatment
(milnacipran versus placebo), and ln(PVI) as predictors
(Table 1). Treatment, ln(PVI), race, and duration of FM
significantly predicted response. Interestingly, individu-
als with increased pain variability were more likely to be
responders. This finding was replicated in a linear
regression analysis using the change in pain (mean at
Figure 1. Pain variability in patients with fibromyalgia. A, Histogram
of pain variability index (PVI) scores for all individuals, showing a
single peak with a relatively large spread. B and C, Consecutive entries
of pain levels for participant 1 and participant 2, respectively. Partic-
ipant 1 displayed relatively consistent levels of pain over time, whereas
participant 2 displayed greater variability. Horizontal lines show the
mean. GBS  Gracely Box Scale.
Table 1. Results of logistic regression analysis of clinical pain re-
sponder status*
Predictor Estimate SEM OR P
ln(PVI) 1.815 0.660 6.143 0.006
Duration of FM, years 0.145 0.062 1.156 0.020
Race (white vs. nonwhite) 1.462 0.643 0.232 0.023
Treatment (milnacipran or placebo) 1.706 0.759 5.507 0.025
Age 0.019 0.023 1.019 0.405
* Each independent variable was force-entered into the following
regression model: logit(responder: 0,1)  ln(pain variability index
[PVI])  duration  race  treatment  age. OR  odds ratio; FM 
fibromyalgia.
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baseline  mean at end) as the dependent variable. A
significant effect of ln(PVI) on change in pain ( 
1.624, P  0.028) was observed after adjusting for age,
duration of FM, race, and baseline pain levels, again
with greater PVI predicting larger improvements in
pain. This association was primarily attributable to
greater changes in pain scores in individuals receiving
placebo. Figure 2A depicts the association between
ln(PVI) and the change in mean pain scores within the 2
study arms. Variability was significantly correlated with
a change in pain for those randomized to placebo (r 
0.460, P  0.02) but not for patients receiving milnaci-
pran (r  0.09, P  0.10).
Association of PVI with nonspecific response to
drug. Because treatment response was associated with
the PVI among placebo responders, we investigated
placebo or nonspecific response patterns in the real-time
pain entries for responders receiving milnacipran (n 
33), over the entire study period. Two major types of
profiles were observed: an exponential decline in pain,
or a linear trend toward reduced pain. Figure 2B shows
the pattern for participant 3, who displayed an exponen-
tial decline in pain, and Figure 2C shows the pattern for
participant 4, who displayed a linear trend. Of the 33
responders given milnacipran, 13 displayed an exponen-
tial pattern, 15 displayed a linear pattern, and 5 had
other patterns of pain. Those displaying a linear decline
in pain had significantly greater baseline pain variability
than those displaying an exponential decline in pain
(mean  SD ln[PVI] 0.73  0.31 linear, 0.47  0.35
exponential; P  0.048).
DISCUSSION
In this study, we explored pain variability in
patients with chronic FM who were participating in a
drug trial. Our results confirm previous findings (5) that
temporal fluctuations in FM pain span a continuum,
with some individuals displaying a large variation in pain
intensity while others have more constant levels.
Pain variability was moderately stable over time.
Individuals in whom pain was classified as highly vari-
able at one time point tended to be classified as having
highly variable pain patterns later. In addition, variabil-
ity in pain was not explained by data-collection artifacts
such as ceiling or floor effects, because pain score
distributions were similar in participants with a large
versus a small PVI. One would expect these distributions
to have differing skewness if floor or ceiling effects were
present. Instead, pain variation was attributable primar-
ily to fluctuations around a stable mean score.
Figure 2. Relationship between the pain variability index (PVI) and
the response to placebo. A, Scatterplot showing the change in mean
pain scores (baseline  end) versus ln(PVI) for individuals receiving
placebo or milnacipran. A significant correlation was observed for
those receiving placebo (r  0.460, P  0.02) but not for individuals
assigned to milnacipran (r  0.09, P  0.10). B and C, Consecutive
diary entries for 2 typical individuals. The plots for participant 3 (B)
and participant 4 (C) showed differing courses following administra-
tion of milnacipran (arrows). Participant 3 displayed an exponential
decline in pain (  7.30 days), whereas participant 4 displayed a linear
trend (slope  0.034/day). Note that participant 4 had increased
variability in pain reporting over the course of the trial, as compared
with participant 3.
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One advantage of this investigation is that we
were able to assess the consequences of pain variability
in a drug trial. We observed that pain variability predicts
drug responsiveness. Individuals with a greater PVI at
baseline were more likely to be responders; this effect
was seen almost exclusively in those randomized to
placebo as compared with those receiving milnacipran,
suggesting that high pain variability may be a predictor
of a placebo response.
If this is correct, one would also predict that this
effect would also be present to some extent within
responders to milnacipran, because placebo mechanisms
should also occur in those randomized to active drug.
Interestingly, our real-time pain data demonstrated that
some milnacipran responders displayed a nonspecific
response to drug (i.e., a gradual linear decline in pain
during milnacipran therapy). Individuals with such a
nonspecific response also had greater baseline pain
variability than those displaying a more immediate (i.e.,
exponential) response.
These results have direct implications for drug
trials in FM and perhaps broader implications for other
pain syndromes. Although we detected no difference in
PVI scores between the 2 study arms in our trial (P 
0.05), investigations that randomize individuals with
greater baseline PVI scores to placebo may be biased
toward the null due to a greater placebo effect. To
counteract or control for this effect, one could either
stratify participants based on baseline PVI scores or
even remove individuals with high pain variability prior
to randomization. Examining the pattern of response to
placebo interventions may also offer further insight into
the mechanisms of placebo-induced analgesia.
This investigation has several limitations. First,
our results may be limited to patients with FM. Second,
participants were enrolled in a drug trial, and the
stability of their pain may have been influenced by
treatment. Third, most participants were women, and as
such our results may not be applicable to a male
population, especially because it is known that women
display changes in pain intensity depending on the time
of their menstrual cycle (16). Fourth, we did not make
an attempt to differentiate systematic versus nonsystem-
atic trends in the data when estimating variability.
Finally, most of our participants were white, thus limit-
ing the applicability of our conclusions to this popula-
tion.
In some patients with FM, the variation in pain
intensity over time is significant. This variability is
relatively constant within individuals and may predict a
nonspecific response to treatment (i.e., a placebo effect).
Extrapolation of these results to other chronic pain
states is warranted.
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